Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OLUTASIDENIB vs OMALIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OLUTASIDENIB vs OMALIZUMAB: Safety Overview

Metric OLUTASIDENIB OMALIZUMAB
Total FAERS Reports 210 63,846
Deaths Reported 27 1,713
Death Rate 12.9% 2.7%
Hospitalizations 85 11,178
Average Patient Age 66.2 yrs 51.0 yrs
% Female Patients 46.3% 72.5%
FDA Approval Date Dec 1, 2022 N/A
Manufacturer Rigel Pharmaceuticals, Inc. CELLTRION, Inc.
Route ORAL SUBCUTANEOUS
Marketing Status Prescription Prescription